Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients

ACTA MEDICA INDONESIANA · Vol. 56 No. 4 (2025)

ISSN
2338-2732, 0125-9326
Terbit
2025-01-21
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: Direct acting antivirals (DAAs) have demonstrated remarkable efficacy, in achieving hepatitis C viral (HCV) elimination rates higher than 90%. One particular concern associated with treatment failure is the emergence of resistance associated substitutions (RASs) in the genome. The occurrence of RASs highlights the adaptability and resilience of the HCV. This highlights the importance of RASs mutation, enabling the development of new therapeutic strategies to combat these resistant strains. This study aims to determine the presence of early HCV mutations in chronic hepatitis C in Indonesia and the association between this mutation to the efficacy of sofosbuvir-daclatasvir. Methods: We conducted a prospective longitudinal study in naïve hepatitis C patient population. The virus was examined for RAS by RNA sequencing before starting treatment. RAS mutations were determined through the cut-off value of RAS mutations that contributed in the successful therapy. All patients were followed up until 12 weeks after completion of treatment to determine the sustained virological response 12 (SVR12). Results: Out of the 58 patients, 9 patients (15.51%) did not achieve SVR. Only 14 patients was further analyzed to provide the association between the mutation and SVR-12 failure after sofosbuvir-daclatasvir therapy. Specifically, 2 patients with L31 mutation and one patient with L31/Y93 mutation achieved SVR. Only one patient with failure to achieve SVR and the mutation was found in Y93H region. Conclusion: The mutation of Y93H may contribute to treatment failure while L31A may increase the susceptibility to DAAs treatment.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 263 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Rino Alvani GaniAfiliasi tidak diketahui12
Andri Sanityoso SulaimanAfiliasi tidak diketahui9
Chyntia Olivia Maurine JasirwanAfiliasi tidak diketahui8
Kemal Fariz KalistaAfiliasi tidak diketahui8
Cosmas Rinaldi A LesmanaAfiliasi tidak diketahui7
Andri SanityosoAfiliasi tidak diketahui5
Ikhwan RinaldiAfiliasi tidak diketahui5
Lutfie LutfieAfiliasi tidak diketahui4
Rino A GaniAfiliasi tidak diketahui3
Marcellus SimadibrataAfiliasi tidak diketahui3
Siti SetiatiAfiliasi tidak diketahui3
Sally Aman NasutionAfiliasi tidak diketahui3
Evy YunihastutiAfiliasi tidak diketahui3
Cosmas Rinaldi Adithya LesmanaAfiliasi tidak diketahui3
Hamzah ShatriAfiliasi tidak diketahui3
Cleopas Martin RumendeAfiliasi tidak diketahui3
Kuntjoro HarimurtiAfiliasi tidak diketahui2
Dicky Levenus TahaparyAfiliasi tidak diketahui2
Imam SubektiAfiliasi tidak diketahui2
Esthika DewiastyAfiliasi tidak diketahui2
Leonard NainggolanAfiliasi tidak diketahui2
Purwita Wijaya LaksmiAfiliasi tidak diketahui2
Muhadi MuhadiAfiliasi tidak diketahui2
Pringgodigdo NugrohoAfiliasi tidak diketahui2
Dyah PurnamasariAfiliasi tidak diketahui2
Murdani AbdullahAfiliasi tidak diketahui2
Adityo SusiloAfiliasi tidak diketahui2
Kaka RenaldiAfiliasi tidak diketahui2
Rudi PutrantoAfiliasi tidak diketahui2
Maulana SuryaminAfiliasi tidak diketahui1
C. Rinaldi A LesmanaAfiliasi tidak diketahui1
Indra WijayaAfiliasi tidak diketahui1
Felix F WidjajaAfiliasi tidak diketahui1
Paramita KhairanAfiliasi tidak diketahui1
Telly KameliaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients</dc:title>
	<dc:creator>Kurniawan, Juferdy</dc:creator>
	<dc:creator>Handayu, Anugrah Dwi</dc:creator>
	<dc:creator>Aprilicia, Gita</dc:creator>
	<dc:creator>Bahri, Darlene Raudhatul</dc:creator>
	<dc:creator>Hasan, Irsan</dc:creator>
	<dc:subject xml:lang="en-US">Hepatitis C</dc:subject>
	<dc:subject xml:lang="en-US">direct acting antiviral</dc:subject>
	<dc:subject xml:lang="en-US">resistance associated substitutions</dc:subject>
	<dc:subject xml:lang="en-US">mutation</dc:subject>
	<dc:subject xml:lang="en-US">Y93H region</dc:subject>
	<dc:description xml:lang="en-US">Background: Direct acting antivirals (DAAs) have demonstrated remarkable efficacy, in achieving hepatitis C viral (HCV) elimination rates higher than 90%. One particular concern associated with treatment failure is the emergence of resistance associated substitutions (RASs) in the genome. The occurrence of RASs highlights the adaptability and resilience of the HCV. This highlights the importance of RASs mutation, enabling the development of new therapeutic strategies to combat these resistant strains. This study aims to determine the presence of early HCV mutations in chronic hepatitis C in Indonesia and the association between this mutation to the efficacy of sofosbuvir-daclatasvir. Methods: We conducted a prospective longitudinal study in naïve hepatitis C patient population. The virus was examined for RAS by RNA sequencing before starting treatment. RAS mutations were determined through the cut-off value of RAS mutations that contributed in the successful therapy. All patients were followed up until 12 weeks after completion of treatment to determine the sustained virological response 12 (SVR12). Results: Out of the 58 patients, 9 patients (15.51%) did not achieve SVR.  Only 14 patients was further analyzed to provide the association between the mutation and SVR-12 failure after sofosbuvir-daclatasvir therapy. Specifically, 2 patients with L31 mutation and one patient with L31/Y93 mutation achieved SVR. Only one patient with failure to achieve SVR and the mutation was found in Y93H region. Conclusion: The mutation of Y93H may contribute to treatment failure while L31A may increase the susceptibility to DAAs treatment.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2025-01-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Cohort Prospective</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2625</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 56 No. 4 (2024): Acta Medica Indonesiana; 451</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2625/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2025 Juferdy Kurniawan, Anugrah Dwi Handayu, Gita Aprilicia, Darlene Raudhatul Bahri, Irsan Hasan</dc:rights>
</oai_dc:dc>